Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quemliclustat - Arcus Biosciences

Drug Profile

Quemliclustat - Arcus Biosciences

Alternative Names: AB-680; Small molecule CD73 inhibitor - Arcus Biosciences

Latest Information Update: 11 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arcus Biosciences
  • Developer Arcus Biosciences; Gilead Sciences; UCLAs Jonsson Comprehensive Cancer Center
  • Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Fluorobenzenes; Phosphonic acids; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action 5-nucleotidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cholangiocarcinoma; Non-small cell lung cancer; Pancreatic cancer
  • Phase I/II Colorectal cancer
  • No development reported Cancer
  • Discontinued Prostate cancer

Most Recent Events

  • 08 Jul 2024 Taiho Pharmaceutical exercises option to in-license Quemliclustat from Arcus Biosciences
  • 08 Jul 2024 Arcus Biosciences plans the phase III PRISM-1 trial for Pancreatic cancer (Combination therapy, First-line therapy, Metastatic disease) in Japan, in 2024
  • 02 Jun 2024 Efficacy and adverse events data from the phase Ib/II ARC-9 trial in Colorectal cancer released by Gilead Sciences
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top